Skip to main content
Midas Edge

Coherus Oncology, Inc.

For the period ended Dec 31, 2024. Filed Mar 17, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 17, 2025

CHRS$0.64-21.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Deficit

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · Other · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Paid-In · ​ · Comprehensive · ​ · Accumulated · ​ · Stockholders'
​ · Shares · ​ · Amount · Capital · Loss · Deficit · Equity (Deficit)
Balances at December 31, 202176,930,096​$7​$1,147,843​$(270)​$(1,049,854)​$97,726
Net loss​—​​—​​—​​—​​(291,754)​​(291,754)
Issuance of common stock upon exercise of stock options​141,897​​—​​691​​—​​—​​691
Issuance of common stock upon vesting of RSUs​806,854​​—​​—​​—​​—​​—
Issuance of common stock under the ESPP​347,883​​—​​2,320​​—​​—​​2,320
Issuance of common stock to Junshi Biosciences, net of issuance costs​916,884​​1​​6,133​​—​​—​​6,134
Taxes paid related to net share settlement of RSUs​(292,098)​​—​​(3,744)​​—​​—​​(3,744)
Stock-based compensation expense​—​​—​​51,188​​—​​—​​51,188
Other comprehensive gain, net of tax​—​​—​​—​​21​​—​​21
Balances at December 31, 2022​78,851,516​​8​​1,204,431​​(249)​​(1,341,608)​​(137,418)
​​​​​​​​​​​​​​​​​​
Net loss​—​—​—​—​(237,892)​(237,892)
Issuance of common stock upon exercise of stock options​430,504​—​694​—​—​694
Issuance of common stock upon vesting of RSUs​1,280,901​—​—​—​—​—
Issuance of common stock under the ESPP​630,348​—​1,809​—​—​1,809
Issuance of common stock in connection with Surface Acquisition:(1)​​​​​​​​​​​​​​​​
Issuance to Surface shareholders for acquisition​11,971,460​​1​​58,540​​—​​—​58,541
Accelerated vesting of equity awards​261,239​​—​​1,053​​—​​—​1,053
Taxes paid related to net share settlement of equity awards​(65,732)​​—​​(347)​​—​​—​​(347)
Issuance of common stock under ATM Offering, net of issuance costs​3,559,761​​1​​18,316​​—​​—​​18,317
Issuance of common stock under Public Offering, net of issuance costs​13,529,411​​1​​53,624​​—​​—​​53,625
Issuance of common stock under Optional Stock Purchase Agreement​2,225,513​​—​​8,179​​—​​—​​8,179
Taxes paid related to net share settlement of RSUs​(459,661)​​—​​(3,527)​​—​​—​​(3,527)
Stock-based compensation expense​—​—​43,540​—​—​43,540
Other comprehensive gain, net of tax​—​​—​​—​​1​​—​1
Balances at December 31, 2023​112,215,260​​11​​1,386,312​​(248)​​(1,579,500)​​(193,425)
​​​​​​​​​​​​​​​​​​
Net income​—​—​—​—​28,507​28,507
Issuance of common stock upon exercise of stock options​174,651​—​291​—​—​291
Issuance of common stock upon vesting of RSUs​816,876​—​—​—​—​—
Issuance of common stock under the ESPP852,222​—​926​—​—​926
Issuance of common stock - partial payout of 2023 bonus in RSUs​1,976,750​​1​​4,407​​—​​—​​4,408
Issuance of common stock under ATM Offering, net of issuance costs​650,005​​—​​1,455​​—​​—​​1,455
Taxes paid related to net share settlement of RSUs​(1,071,216)​​—​​(2,476)​​—​​—​​(2,476)
Stock-based compensation expense​—​—​28,351​—​—​28,351
Other comprehensive loss, net of tax—​​—​​—​​(27)​​—​(27)
Balances at December 31, 2024115,614,548​$12​$1,419,266​$(275)​$(1,550,993)​$(131,990)
(1)See Note 6 for further discussion.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.